65,437 trials
Chronic Myeloid Leukemia · Blast Crisis
Primary: Major and Overall Hematologic Response (MaHR and OHR) — 2; 34; 36; 4 Participants
Chronic Myelogenous Leukemia
Primary: Major and Overall Hematologic Response (MaHR and OHR) — 9; 103; 112; 12 participants
Papillomavirus Type 16/18 Infection · Cervical Intraepithelial Neoplasia
Primary: Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Antibodies — 1440.4; 1903.7; 3861.7; 1397.5 EL.U/mL
Healthy
Primary: AUC0-144 (Area Under the Concentration-time Curve From Time Zero to 144 Hour Post-dose) — 114386.56; 105377.55 ng*h/mL — p=<0.05
Cervical Intraepithelial Neoplasia · Papillomavirus Infection
Primary: Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Antibodies — 3901.6; 3226.3; 2688.6; 2395.8 EL.U/mL
Irritable Bowel Syndrome
Primary: Overall Bowel Symptom Scores (BSS) — 76; 44 Scores on a scale
Urinary Tract Infection
Primary: Microbiological Response Assessment Profile — 58; 63 Participants
Rheumatoid Arthritis
Primary: Number of Participants Meeting American College of Rheumatology 20% (ACR20) Response Criteria at Week 24 — 129; 131; 59 Participants — p=<0.001
Major Depressive Disorder
Primary: HAM-D 17 (Hamilton Depression Rating Scale) — 1.0; 18.5 Units on a scale
Pneumonia
Primary: Clinical Cures in the Intent to Treat Population — 213; 224; 21; 9 Participants — p=0.0769
Attention Deficit/Hyperactivity Disorder (ADHD)
Primary: Conners Rating Scale - School Version — -0.44; -1.73; -2.63; -0.63 Scores on a scale
Primary Hypercholesterolemia
Primary: Number of Participants Reaching the Targeted LDL-C Levels — 740 Participants
HIV Infections · AIDS Virus · Human Immunodeficiency Virus
Primary: Virological Response [Per Protocol (PP) - Time to Loss of Virologic Response (TLOVR), < 50 Copies/ml, Week 48] — 108; 106 participants
Alzheimer's Disease · Oxidative Stress · Dementia
Primary: F2-isoprostane Level Urine F2-Isoprostanes — 0.40; -2.02; 0.45 nanogram per miligram — p=0.83
Colorectal Cancer
Primary: Weekly Steady-state Exposure of Bevacizumab — 4090.3; 4022.4 day*ug/mL